Emergent BioSolutions Balance Sheet Health
Financial Health criteria checks 2/6
Emergent BioSolutions has a total shareholder equity of $649.3M and total debt of $860.2M, which brings its debt-to-equity ratio to 132.5%. Its total assets and total liabilities are $1.8B and $1.2B respectively.
Key information
132.5%
Debt to equity ratio
US$860.20m
Debt
| Interest coverage ratio | n/a |
| Cash | US$111.70m |
| Equity | US$649.30m |
| Total liabilities | US$1.17b |
| Total assets | US$1.82b |
Recent financial health updates
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet
Apr 24Recent updates
New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued
Feb 16Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M
Feb 15Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
Dec 07Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance
Nov 09Emergent doses first participant in Phase 1 trial for Lassa virus vaccine
Sep 06Emergent BioSolutions: Now Long Through Sale Of October Put Spreads
Aug 24A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)
Aug 13Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant
Aug 12Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss
Aug 01Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
Jul 26Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig
Jul 06Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
May 29Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate
May 12Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet
Apr 24Financial Position Analysis
Short Term Liabilities: EBS's short term assets ($679.5M) exceed its short term liabilities ($651.3M).
Long Term Liabilities: EBS's short term assets ($679.5M) exceed its long term liabilities ($522.6M).
Debt to Equity History and Analysis
Debt Level: EBS's net debt to equity ratio (115.3%) is considered high.
Reducing Debt: EBS's debt to equity ratio has increased from 78.6% to 132.5% over the past 5 years.
Debt Coverage: EBS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if EBS's interest payments on its debt are well covered by EBIT.